Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Rating Upgraded by Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Y-mAbs Therapeutics (NASDAQ:YMAB) from a sell rating to a hold rating in a report published on Saturday morning, Zacks.com reports.

According to Zacks, “Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company’s product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA. “

A number of other equities research analysts have also recently commented on YMAB. Cowen reiterated a buy rating on shares of Y-mAbs Therapeutics in a report on Monday, July 1st. Wedbush started coverage on Y-mAbs Therapeutics in a report on Tuesday, September 3rd. They set an outperform rating and a $38.00 target price on the stock. Finally, HC Wainwright set a $40.00 target price on Y-mAbs Therapeutics and gave the company a buy rating in a report on Monday, August 26th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $32.50.

YMAB opened at $25.14 on Friday. The stock has a market cap of $869.69 million and a P/E ratio of -16.76. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.04 and a quick ratio of 9.04. The stock’s 50 day simple moving average is $27.55 and its 200 day simple moving average is $24.27. Y-mAbs Therapeutics has a 1-year low of $15.17 and a 1-year high of $32.27.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.05). Research analysts expect that Y-mAbs Therapeutics will post -2.1 EPS for the current fiscal year.

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 4,000 shares of the stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $22.54, for a total transaction of $90,160.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Johan Wedell-Wedellsborg sold 168,244 shares of the stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $27.57, for a total value of $4,638,487.08. The disclosure for this sale can be found here. In the last quarter, insiders have sold 344,010 shares of company stock worth $9,324,188. 38.40% of the stock is owned by insiders.

Several institutional investors have recently modified their holdings of YMAB. BlackRock Inc. lifted its stake in shares of Y-mAbs Therapeutics by 212.6% during the 2nd quarter. BlackRock Inc. now owns 1,153,831 shares of the company’s stock worth $26,387,000 after purchasing an additional 784,672 shares during the period. Artal Group S.A. purchased a new position in shares of Y-mAbs Therapeutics during the 2nd quarter worth $9,148,000. Cormorant Asset Management LP lifted its stake in shares of Y-mAbs Therapeutics by 39.8% during the 2nd quarter. Cormorant Asset Management LP now owns 1,000,000 shares of the company’s stock worth $22,870,000 after purchasing an additional 284,518 shares during the period. Vanguard Group Inc. lifted its stake in shares of Y-mAbs Therapeutics by 72.0% during the 2nd quarter. Vanguard Group Inc. now owns 489,582 shares of the company’s stock worth $11,196,000 after purchasing an additional 205,021 shares during the period. Finally, AXA purchased a new position in shares of Y-mAbs Therapeutics during the 2nd quarter worth $3,560,000. 32.06% of the stock is currently owned by institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Featured Story: Do Tariffs Work?

Get a free copy of the Zacks research report on Y-mAbs Therapeutics (YMAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Weekly Investment Analysts’ Ratings Changes for Inter Pipeline
Weekly Investment Analysts’ Ratings Changes for Inter Pipeline
Henry Boot  Stock Rating Reaffirmed by Peel Hunt
Henry Boot Stock Rating Reaffirmed by Peel Hunt
Marshalls  Receives Add Rating from Peel Hunt
Marshalls Receives Add Rating from Peel Hunt
Peel Hunt Reaffirms “Hold” Rating for Savills
Peel Hunt Reaffirms “Hold” Rating for Savills
$1.70 Billion in Sales Expected for Packaging Corp Of America  This Quarter
$1.70 Billion in Sales Expected for Packaging Corp Of America This Quarter
FY2019 EPS Estimates for Acer Therapeutics Inc Decreased by William Blair
FY2019 EPS Estimates for Acer Therapeutics Inc Decreased by William Blair


© 2006-2019 Ticker Report